Sharechat Logo

North Shore financial adviser Cherry pleads guilty to $5M fraud

Friday 7th September 2012

Text too small?

Albany-based financial adviser Evan Cherry pleaded guilty to four charges out of seven levelled against him in a $5 million fraud in the North Shore District Court today.

Cherry admitted four charges under the Crimes Act relating to the misappropriation of investor funds and false statements in investor reports and has been remanded in custody until sentencing on Dec. 11, the Serious Fraud Office said in a statement.

The fraud took place between January 2001 and February 2007 when funds were invested contrary to investors' instructions, the bulk of whom had followed him when he left a large firm.

"The high level of trust associated with personal relationships reduces any questioning by the investor when presented with a change in the underlying nature of the investment," chief executive Adam Feeley said. "It can be a dangerous arrangement that clouds judgement."

Cherry's ISL group of companies received some $9 million from about 175 investors, the SFO said.

The SFO began its investigation in June last year after the Financial Markets Authority's predecessor, the Securities Commission, referred the case.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors